Isomorphic Labs has raised $5 billion in Series C funding as it prepares AI-designed drug candidates for clinical trials. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining existing backers that include Alphabet’s GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.

The company was spun out of Google DeepMind in 2021 and builds simulation models for chemistry and drug design. Its platform extends work related to AlphaFold, the protein-structure prediction system. Isomorphic says programs in oncology and immunology have produced positive preclinical results, and it has partnerships with Eli Lilly, Novartis and Johnson & Johnson.

The new capital will fund further development of the design engine and expansion into additional areas of medicine. It follows a $2.1 billion Series B completed in May, giving the company two unusually large rounds within six months. Isomorphic did not disclose its current valuation; an earlier report said it had sought funding at about $50 billion.

Preclinical results do not establish that a treatment is safe or effective in people. Moving candidates into trials will test whether faster computational design translates into viable medicines after laboratory, manufacturing and regulatory hurdles. The round gives Isomorphic substantial resources for that process, but clinical evidence rather than model sophistication will determine the platform’s medical impact.